Program
Anti-ROR1 Antibody-drug Conjugate IM-1021
Its studies are mostly in Hematologic Neoplasms, led by Immunome.
Furthest: phase 1, since Feb 4, 20251 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunome | 11 open or running | phase 1since Feb 4, 2025 | Feb 4, 2025 | May 2028phase 1 · NCT06823167 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2025First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT06823167 · 190 planned · United States, Denmark, France and more
Ahead
- May 2028Primary completion: phase 1 study in Hematologic NeoplasmsNCT06823167
TargetBeta
ROR1 →read by rule
“An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) ”NCIt, by rule
Other programs on ROR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zilovertamab vedotin | Merck | phase 3 | 10 |
| Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07rule | shanghai-epimab-biotherapeutics-co-ltd | phase 2 | 2 |
| TQB2101 | Sino Biopharmaceutical | phase 1 | 2 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06823167Hematologic Neoplasms · United States, Denmark, France and more | 1 | Recruiting | May 2028 | 190 |
How it is read
Names in the registry
- “IM-1021”, 1 entry
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.